Corneal Cross-Linking Treatment: How Port Jefferson Station Eye Doctors Are Stopping Keratoconus Progression with FDA-Approved Procedures

Revolutionary Corneal Cross-Linking Treatment in Port Jefferson Station: How FDA-Approved Procedures Are Transforming Keratoconus Care

For the millions of Americans living with keratoconus, a progressive eye condition that causes the cornea to thin and bulge outward, the fear of worsening vision has long been a constant concern. Approximately 90% of cases of keratoconus are bilateral and as many as 20% of untreated keratoconus patients ultimately require a corneal transplant. However, breakthrough FDA-approved corneal cross-linking treatments are now changing the landscape of keratoconus care, offering patients in Port Jefferson Station and beyond new hope for preserving their vision.

Understanding Keratoconus and Its Impact

Keratoconus is a progressive corneal disorder that affects the clear, dome-shaped front surface of the eye. Keratoconus is a progressive eye condition that affects the structure of the cornea, the clear front surface of the eye. In a healthy eye, the cornea maintains a smooth, rounded shape. With keratoconus, the cornea gradually thins and begins to bulge outward into a cone-like shape. This irregular shape distorts vision, causing blurred sight, increased sensitivity to light, and difficulty with daily activities.

Conventional keratoconus treatments such as eyeglasses or contact lenses address visual symptoms only and do not slow or halt underlying disease progression. Without intervention, the condition can progress to the point where a corneal transplant becomes necessary, making early detection and treatment crucial for preserving long-term vision.

The Science Behind Corneal Cross-Linking

Corneal cross-linking is a minimally invasive procedure designed to strengthen the cornea. It uses riboflavin (vitamin B2) eye drops combined with controlled ultraviolet-A (UV-A) light to create new chemical bonds—called cross-links—between collagen fibers in the cornea. These additional bonds increase corneal rigidity, helping the cornea maintain its shape and resist further thinning and bulging.

Corneal collagen cross-linking is a medical procedure designed to strengthen the cornea. It works by increasing the number of natural bonds (or “cross-links”) between collagen fibers in the cornea. These additional cross-links make the cornea stiffer and more resistant to further thinning or bulging.

FDA-Approved Treatment Options

The FDA has approved multiple corneal cross-linking treatments, providing patients with safe and effective options. Glaukos’ first-generation corneal cross-linking therapy, known as Photrexa® Viscous / Photrexa®, which requires removal of the corneal epithelium, received U.S. FDA approval in 2016 as an orphan drug and has since been the first-and-only FDA-approved corneal cross-linking therapy for the treatment of keratoconus.

In a major advancement for patient care, In October of 2025, the U.S. Food & Drug Administration (FDA) approved Epioxa, ushering in a novel cross linking procedure for patients with keratoconus. It is the first FDA-approved incision-free, topical cross-linking therapy for keratoconus. This breakthrough represents a significant improvement in patient comfort and recovery time.

The Revolutionary Epi-On Approach

Traditional corneal cross-linking procedures require removal of the corneal epithelium, the thin outer surface layer of the eye. However, the newly approved Epioxa treatment offers an “epithelium-on” or “epi-on” approach. Instead of surgically removing the outer layer of the cornea (the epithelium) and applying riboflavin and UV as in the classic “epi-off” cross-linking procedure, Epioxa allows treatment while the epithelium remains intact (“epi-on”), thus reducing invasiveness.

This advancement offers several key benefits for patients:

  • No epithelium removal ― The “epi-on” approach preserves the outer corneal layer, meaning less trauma, less pain and quicker recovery.
  • The novel topical treatment does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.
  • Epioxa uses specially formulated, oxygen-enriched riboflavin solutions that are designed to penetrate the intact epithelium. The drops are activated with UV light in an oxygen-rich environment, allowing effective cross-linking while improving patient comfort and recovery time.

Treatment Effectiveness and Clinical Results

Findings showed CXL treatment led to a statistically significant improvement based on the change from baseline in Kmax vs vehicle control at 6 months (treatment difference, -0.6 D [95% CI, -0.9, -0.2]; P <.01) and at 12 months (treatment difference, -1.0 D [95% CI, -1.3, -0.6]; P <.01). The clinical trials supporting FDA approval involved more than 400 patients, demonstrating the treatment's safety and efficacy.

There are more than 300 peer-reviewed publications supporting the performance and safety of Glaukos’ cross-linking therapies. This extensive research base provides confidence in the treatment’s long-term benefits for patients with progressive keratoconus.

Expert Eye Care in Port Jefferson Station

For residents of Port Jefferson Station seeking advanced keratoconus treatment, North Shore Advanced Eye Care (NSAEC) provides comprehensive eye care services to the Suffolk County community. Led by Dr. Edward J. Moylan, the practice combines cutting-edge technology with personalized care to ensure the unique needs of each patient are met. Their services cover a wide range of needs from contact lens fittings to LASIK co-management and emergency eye care.

When searching for an optometrist port jefferson station, patients benefit from NSAEC’s commitment to personalized care. Our office provides quality comprehensive care with a very personal touch. North Shore Advanced Eye Care is proud of our over 25 years of service in the Suffolk, County area, we’ve grown to know the people and the community and to understand their cares and concerns.

Who Is a Candidate for Corneal Cross-Linking?

Epioxa is approved for adults and pediatric patients aged 13 years and older with keratoconus. Candidates typically demonstrate evidence of progressive disease. Early intervention is crucial, as keratoconus is progressive, early diagnosis and timely treatment are critical to preserving long-term vision.

It’s important to understand that cross-linking does not reverse keratoconus or eliminate the need for glasses or contact lenses. Instead, its primary goal is to stop or slow progression, preserving vision and reducing the likelihood of needing more invasive procedures such as corneal transplantation.

Insurance Coverage and Accessibility

One of the significant advantages of FDA-approved treatments is insurance coverage. Insurance coverage for FDA approved cross-linking with Photrexa® Viscous, Photrexa® and the KXL® System is now widely available. Greater than 95% of the commercially insured population has access to this potentially sight-protecting treatment.

The Future of Keratoconus Treatment

The recent FDA approval of epi-on cross-linking represents a paradigm shift in keratoconus care. The company behind Epioxa, Glaukos Corporation, expects commercial availability in Q1 2026 (early 2026). This means patients will soon have access to this less invasive treatment option with improved comfort and faster recovery times.

The FDA approval of epi-on corneal cross-linking represents a significant advancement in keratoconus care. For patients in Port Jefferson Station and throughout Suffolk County, this advancement offers new hope for managing their condition with greater comfort and convenience.

Taking the Next Step

If you or a loved one has been diagnosed with keratoconus or are experiencing symptoms such as blurred vision, light sensitivity, or frequent changes in prescription, it’s essential to seek evaluation from an experienced eye care professional. Early detection and treatment can make a significant difference in preserving vision and preventing the need for more invasive procedures.

The combination of FDA-approved treatments and expert local care means that patients in Port Jefferson Station have access to the most advanced keratoconus treatments available. With the promise of new, less invasive options becoming available soon, there has never been a better time to explore your treatment options and take control of your eye health.